Mutual of America Capital Management LLC Sells 4,109 Shares of Organon & Co. $OGN

Mutual of America Capital Management LLC decreased its position in Organon & Co. (NYSE:OGN) by 11.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,394 shares of the company’s stock after selling 4,109 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Organon & Co. were worth $323,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Hanson & Doremus Investment Management bought a new stake in Organon & Co. in the 2nd quarter worth about $26,000. Ransom Advisory Ltd bought a new stake in Organon & Co. in the 1st quarter worth about $32,000. Brooklyn Investment Group grew its holdings in shares of Organon & Co. by 1,012.3% in the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock valued at $46,000 after acquiring an additional 2,794 shares in the last quarter. Ridgewood Investments LLC bought a new position in shares of Organon & Co. in the second quarter valued at approximately $48,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Organon & Co. in the first quarter valued at approximately $51,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 4.6%

OGN stock opened at $6.36 on Thursday. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of 2.36, a PEG ratio of 0.60 and a beta of 0.63. Organon & Co. has a fifty-two week low of $6.32 and a fifty-two week high of $19.05. The stock has a fifty day moving average of $9.76 and a 200-day moving average of $9.78.

Organon & Co. (NYSE:OGN) last issued its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.06. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The company’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter last year, the business earned $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were issued a $0.02 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 annualized dividend and a yield of 1.3%. Organon & Co.’s dividend payout ratio (DPR) is 2.97%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price for the company. in a report on Monday. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.